The Huntleigh Healthcare Ltd Sonicaid FM820 and FM830 Encore fetal monitors are indicated for use by trained healthcare professionals in non-invasive monitoring of physiological parameters in pregnant adult human females, and fetuses, during the intrapartum and antepartum periods of pregnancy. The devices are intended for use in clinical and hospital-type facilities. They are not intended for use in intensive care units, operating rooms or in transport monitoring applications.

Sonicaid FM820E is suitable for use when there is a need to monitor the following physiological parameters:

. Single or twin fetal heart rates by means of ultrasound
◆ Fetal or maternal heart rate via ECG
Uterine activity externally or internally sensed .
. Fetal movement - maternally sensed.

Sonicaid FM830E is suitable for use when there is a need to monitor the following physiological parameters:

. Single or twin fetal heart rates by means of ultrasound
. Fetal or maternal heart rate via ECG
Uterine activity externally or internally sensed .
Fetal movement - maternally sensed.
. Maternal heart rate and oxygen saturation via pulse oximetry
. Maternal non-invasive blood pressure

Device Description

The FM820E and FM830E are fetal/maternal monitors designed for use in clinical and hospital environments during the ante-partum and intra-partum phases of pregnancy.

Both units are designed for use at the bedside and the range includes a wall mounting bracket and a trolley for fixed or transportable use. The units may also be used free-standing on a work surface.

The FM820E and FM830E are powered from the local mains electrical supply.

The FM820E includes the following facilities:

Monitoring of one or two fetal heart rates via two independent ultrasound transducers. .
Monitoring of maternal uterine activity either via external (Toco) or internal (IUP) transducers. .
Monitoring of maternal or fetal heart rate via ECG.
. Capture of maternally sensed fetal movements via cabled switch.
Display of vital signs parameters via colour LCD screen. .
t Control interface via combination of dedicated and "soft" function buttons in conjunction with on-screen prompts.
. Chart printout via inbuilt thermal printer.
Connection to Central Monitoring System possible via RS232 or Ethernet. .
Audio and visual alerts (user set limits).

The following facilities are provided on the FM830E model in addition to the above:

. Monitoring of maternal oxygen saturation and heart rate via pulse oximetry sensor.
Monitoring of maternal Non-Invasive Blood Pressure (NIBP) via inflatable cuff. .

The connections for the additional facilities are incorporated in a "side pod", which extends the area of the front panel. Field upgrade of the FM820E to FM830E specification is not allowed.

AI/ML Overview

The provided text describes the Sonicaid FM800, a fetal/maternal monitor, and its comparison to predicate devices, but it does not include detailed acceptance criteria or a dedicated study definitively proving the device meets specific performance criteria in the format requested.

Instead, the document focuses on demonstrating substantial equivalence to existing legally marketed devices (Sonicaid FM830 (K002150) and RDT Limited Tempus IC™ Patient Monitor (K082718)) for FDA 510(k) premarket notification. This means the manufacturer is asserting their new device is as safe and effective as a device already on the market, rather than conducting a de novo study against pre-defined acceptance criteria for a novel device.

However, I can extract the relevant information and present what is available in a structured manner, highlighting the limitations.

Here's the breakdown of the information requested, based on the provided text:

Acceptance Criteria and Device Performance Study for Sonicaid FM800

Based on the provided FDA 510(k) summary for the Sonicaid FM800, the device aims to demonstrate substantial equivalence to predicate devices rather than meeting specific, explicitly stated acceptance criteria from a de novo study. Therefore, the "acceptance criteria" are implied by the performance of the predicate devices. The study conducted to support this is primarily comparative bench testing and reliance on OEM-provided clinical data.

1. A table of acceptance criteria and the reported device performance

Since specific, quantitative acceptance criteria are not explicitly defined in the document for general device performance (like sensitivity/specificity for a diagnostic device), I will use the comparison to the predicate device's characteristics and the documented performance improvements as a proxy.

Characteristic	Predicate Device (Sonicaid FM830 (K002150)) Performance	Submitted Device (Sonicaid FM830 Encore) Performance	Rationale/Implied "Acceptance"
Human Interface			Improved Presentation
Display	Monochrome Electroluminescent 320x240	Colour LCD 320x240	Clearer user interface, reduced power consumption.
Controls	Membrane type push buttons with dedicated and "soft" keys	Membrane type push buttons with dedicated and "soft" keys	Same, implying equivalence.
Printer	128mm Thick Film Thermal Array, 8 dots/mm	128mm Thick Film Thermal Array, 8 dots/mm	Same, implying equivalence.
Connectors	(Varied connector types)	(Updated connector types)	Modernized, improved patient isolation (plastic vs metal for MSpO2).
Power Requirements	Auto-switches 100-120 & 200-240Vac; 100VA max.	90-240Vac; 100VA max.	Increased supply flexibility, same consumption. Implies improved adaptability.
Ultrasound			Improved Signal Processing & Reduced Acoustic Output
Transducers - Physical	74x27mm (Dia x Height); 7-element piezo	79x27mm (Dia x Height); 8-element piezo	Similar, implies functional equivalence.
Transducers - Frequency	1.5MHz (US1) and 2MHz (US2)	1MHz (both channels)	Improved pickup & discrimination with new software.
Measured Acoustic Output (Ispta) (FDA Track 1)	1.5MHz: 11mW cm-2; 2.0MHz: 7.3mW cm-2	2.1mW cm-2	Superior signal processing enabled reduction in acoustic power output (a safety improvement).
Audio Feedback	Analogue	Digital	Improved artefact rejection, better audibility at 1MHz.
Tocograph			Improved Patient Comfort & Maintenance
Transducers - Physical	Floating piston type with adhesive membrane.	New moulding, similar to u/s with overmoulded elastomer faceplate.	Lower maintenance, improved patient comfort, easier to clean, reduced infection risk.
MECG/FECG			Performance Improvement under Sub-optimal Conditions
Signal Processing	Analogue/digital.	Analogue/digital (enhanced)	Performance improvement under sub-optimal conditions.
NIBP	Suntech Alta OEM Technology	Suntech Advantage OEM Technology	Superseded, implying updated and equivalent/improved performance.
MSPO2	BCI (Smiths Medical) WW3711 "B2" OEM Technology	BCI (Smiths Medical) WW3711 "B2" OEM Technology	Same OEM module, ensuring equivalent performance.
Software	Not implemented (CTG Trace)	Trace data stored in memory for review on screen - up to 72 hours.	Product improvement (enhanced functionality).

2. Sample size used for the test set and the data provenance (e.g. country of origin of the data, retrospective or prospective)

Test Set Sample Size:
- For non-clinical bench testing: The document does not specify a "sample size" in terms of number of cases or patients for the comparative bench testing (document 7515101 - FM800E Comparative Bench Test Summary) or the MsP02 verification protocol (document 7514502), although these would involve laboratory tests on the device itself.
- For clinical tests: "No specific clinical tests were carried out to determine substantial equivalence." The submission references clinical trials carried out by the OEM providers of the SpO2 technology, but the sample size for these external OEM trials is not provided within this document. User evaluation trials are proposed but not yet completed at the time of submission.
Data Provenance:
- Bench Testing: Conducted internally by Huntleigh Healthcare Ltd. (United Kingdom). This would be prospective for the submitted device, comparing it against the predicate.
- OEM SpO2 Clinical Trials: Conducted by BCI (Smiths Medical). The country of origin and whether these were retrospective or prospective are not specified in this document.

3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts (e.g. radiologist with 10 years of experience)

The document does not mention using experts to establish ground truth for the test set as part of its own substantial equivalence testing. The primary test method was comparative bench testing against a predicate device.
For the OEM SpO2 clinical trials, details about expert involvement for ground truth are not provided in this submission.

4. Adjudication method (e.g. 2+1, 3+1, none) for the test set

No adjudication method is mentioned for any test set within this submission. The tests performed are primarily engineering bench tests or rely on external OEM clinical data.

5. If a multi-reader multi-case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance

No MRMC study was done. This device is a medical monitor, not an AI-powered diagnostic imaging tool that would typically involve human readers. The document states that user evaluation trials are proposed to verify effectiveness in clinical situations, but these are not described as MRMC studies and were not completed at the time of submission.

6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done

The device is a monitor that provides physiological parameters. Its performance is inherent in its measurement accuracy and display, which can be evaluated in a standalone manner (e.g., how accurately it measures heart rate or blood pressure compared to a reference). The "Comparative bench tests" confirm this standalone performance. No specific standalone performance metrics (e.g., algorithm only) as might be seen in an AI context are provided, but the device itself has standalone performance.

7. The type of ground truth used (expert consensus, pathology, outcomes data, etc)

For the bench tests, the "ground truth" is typically established by using calibrated reference equipment or standards to ensure the new device's readings are accurate and comparable to the predicate device.
For the OEM SpO2 clinical trials, the type of ground truth for oxygen saturation would likely involve co-oximetry, the gold standard for blood oxygen measurement. However, this is not detailed in the provided text.

8. The sample size for the training set

The device is a traditional medical monitor; it is not described as utilizing machine learning or artificial intelligence that would require a "training set" in the computational sense. The "improved signal processing" or "enhanced" algorithms refer to conventional digital signal processing, not AI model training. Therefore, this question is not applicable.

9. How the ground truth for the training set was established

This question is not applicable as there is no "training set" for an AI model mentioned for this device.

Summary

{0}------------------------------------------------

sonicaid FM800

Fetal Monitor

FDA 510(k) Premarket Notification

Section 5

510(k) Summary

Huntleigh Healthcare Ltd.

Page 5.1 FM800E FDA 510(k) Premarket Notification

{1}------------------------------------------------

510(k) Summar

Diagnostic Products Division

5.1 APPLICANT INFORMATION

Submitter:	Huntleigh Healthcare LimitedDiagnostic Products Division
Address:	Unit 35, Portmanmoor RoadCardiffCF24 5HNUnited Kingdom
Telephone:	(44) 2920 485885
Fax:	(44) 2920 492520
Contact:	Graham Booth
Prepared:	26 January 2009

5.2 DEVICE INFORMATION

Proprietary Name:	Sonicaid FM820E and FM830E (E=Encore)
Common/Classification Name:	Perinatal Monitoring Device & Accessories

5.3 IDENTIFICATION OF LEGALLY MARKETED DEVICES TO WHICH EQUIVALENCE IS CLAIMED

Predicate Device 1:	Sonicaid FM830 (K002150)
Predicate Device 2:	RDT Limited Tempus IC™ Patient Monitor (K082718)

5.4 NEW DEVICE DESCRIPTION

5.4.1 Outline

The FM820E and FM830E are fetal/maternal monitors designed for use in clinical and hospital environments during the ante-partum and intra-partum phases of pregnancy.

Both units are designed for use at the bedside and the range includes a wall mounting bracket and a trolley for fixed or transportable use. The units may also be used free-standing on a work surface.

The FM820E and FM830E are powered from the local mains electrical supply.

The FM820E includes the following facilities:

Monitoring of one or two fetal heart rates via two independent ultrasound transducers. .
Monitoring of maternal uterine activity either via external (Toco) or internal (IUP) transducers. .
Monitoring of maternal or fetal heart rate via ECG. �
. Capture of maternally sensed fetal movements via cabled switch.
Display of vital signs parameters via colour LCD screen. .
t Control interface via combination of dedicated and "soft" function buttons in conjunction with on-screen prompts.
. Chart printout via inbuilt thermal printer.
Connection to Central Monitoring System possible via RS232 or Ethernet. .

{2}------------------------------------------------

Audio and visual alerts (user set limits).
The following facilities are provided on the FM830E model in addition to the above:
. Monitoring of maternal oxygen saturation and heart rate via pulse oximetry sensor.
Monitoring of maternal Non-Invasive Blood Pressure (NIBP) via inflatable cuff. .

The connections for the additional facilities are incorporated in a "side pod", which extends the area of the front panel. Field upgrade of the FM820E to FM830E specification is not allowed.

5.4.2 Technology & Operating Principles

5.4.2.1 Ultrasound

The ultrasound channels use identical transducers, each incorporating 8 ceramic piezo elements electrically connected in parallel. The operating principle is as follows:

The monitor drives the transducer with an excitation signal, comprising a "burst" of ac electrical current at the nominal operating frequency of the transducer. The piezo elements have a characteristic response of a tuned circuit, leading to highest efficiency at a particular nominal frequency – in this case 1MHz.

The choice of frequency, the geometry and size of the individual elements, and their arrangement within the transducer affects the achievable degree of penetration, beam width and discrimination.

After each burst, the monitor "listens" for signals picked up by the transducer, which now acts as a pickup device, with peak response at the characteristic frequency. These signals will be acoustic reflections of the original transmitted burst, delayed in time according to the distance travelled within the body of the mother, and the fetus. The Doppler Effect causes reflections from moving body parts to reflect signals with a shift in frequency; it is these frequency-shifted reflections that are detected and processed within the unit to determine fetal heart activity. Audible feedback is provided to enable the operator to direct the "beam" of ultrasound so as to provide optimal pickup of the fetal heart activity, recognisable by a characteristic sound. Once the optimum location has been found, the transducer is held in place by an elasticated belt.

The second ultrasound transducer is similarly used in the case of a twin pregnancy.

The signals obtained from the ultrasound channels are digitally processed to extract the fetal heart rate(s).

The ultrasound channels rely on the transducer insulation from the circuitry of the FM800E, which is referenced to mains earth.

5.4.2.2 Toco/IUP

The tocograph transducer is a pressure sensitive device that is strapped to the mother's stomach with an elasticated belt. The central part of the contact area is in the form of an elastic membrane that is free to move with respect to the main body of the device. Contractions of the uterus cause changes in pressure on the membrane and these are translated to electrical signals by means of strain gauges mounted on an internal steel spring.

The IUP sensor is an alternative method of picking up contractions. A pressure-sensitive probe is inserted into the birth canal and directly monitors changes in uterine pressure. The IUP probe is a presterilised single use device.

The tocograph and IUP sensors use similar principles (strain gauge bridges). Being two alternatives for measuring the same parameter, they are mutually exclusive. The two devices use the same input connector and signal processing circuitry. The type of transducer in use (Toco or IUP) is identified by electrical coding of the connections.

{3}------------------------------------------------

The signals derived from the tocograph and IUP sensor are digitised and processes display.

The Toco/IUP channel is electrically isolated from the main circuitry of the FM800E by transformer and optical isolators.

5.4.2.3 ECG

The FM800E has one ECG channel, which can be used for monitoring either maternal or fetal heart rates.

Maternal ECG signals are derived from two contact pads placed on the mother's torso. A "reference" connection is also made - either via a third pad, or an electrode strapped to the leg.

Fetal ECG signals are derived from a scalp clip, which provides the two signal connections. The reference connection is made via an electrode strapped to the mother's leg.

The FM800E uses an "active reference drive", whereby the reference electrode is incorporated within a negative feedback loop and driven with the inverse of the common-mode signal derived from the two signal electrodes. This acts to reduce common-mode signal and improves signal to noise ratio. The ECG channel also has an "active screen (shield) drive", which ensures that the cable screen (shield) is maintained close to the common-mode potential, further negating interference effects. This drive signal is not a patient contact signal.

The ECG channel signal is digitised and processed for printout and display.

Maternal heart rate information is naturally useful for monitoring of the mother. However, the FM800E also cross-checks the maternal HR derived from the ultrasound channel(s) and provides a warning if there is similarity. This helps prevent false monitoring of maternally derived HR signals, which is a major risk in fetal monitoring.

Fetal ECG provides a more reliable signal during the intrapartum stage.

The ECG channel is electrically isolated from the main circuitry of the FM800E by transformer and optical isolators. The type of transducer in use (Maternal or Fetal) is identified by electrical coding of the connections so that from the user perspective, selection is "automatic".

5.4.2.4 Fetal Event Marker

A simple push button switch is provided to capture fetal movements sensed by the mother. Pressing the switch causes a message to be briefly displayed on the screen, and a marker to be printed on the tocograph trace.

The Fetal Event Marker input relies on the switch insulation from the circuitry of the FM800E, which is referenced to mains earth.

5.4.2.5 Maternal SpO2

This facility is incorporated in the FM830E version only (i.e. not the FM820E). It uses a third party module, which provides a data signal to the FM830E's processing system.

In use, a sensor, in the form of a spring-loaded clip, is placed on the mother's finger. The sensor emits two wavelengths of light, one red and one infrared, through body tissue to a photodetector. The principle of operation is on the basis that oxygen-rich blood absorbs less red light than oxygen depleted blood. The maternal oxygen saturation and heart rate are derived and passed to the FM830E's processing system in the form of a serial data stream. This information is displayed on the screen and printed on the chart.

Apart from being used to monitor the well-being of the mother, as with MECG, the FM830E also crosschecks the SpO2 derived MHR with the fetal HR derived from the ultrasound and/or FECG channel(s) and provides a warning in the event of coincidence.

{4}------------------------------------------------

Interface with the patient is in the form of low energy light transmission only, electrical isolation. In addition, this section is isolated from the main electronics by transform optical isolators.

5.4.2.6 Maternal Non-Invasive Blood Pressure

This facility is incorporated in the FM830E version only (i.e. not the FM820E). It uses a third party module, which provides a serial stream to the FM830E's processing system.

In use, an inflatable cuff is placed around the mother's arm. A measurement cycle begins with the cuff being inflated; the system senses both the cuff pressure, and the oscillometric signal generated by arterial pulses. From these, the systolic blood pressures are determined, along with the MHR. The cycle ends with the cuff being deflated. Measurements can be made manually, on an asrequired basis, or the FM830E can be set to take measurements periodically.

The NIBP module incorporates fail-safe mechanisms to prevent over-inflation of the cuff, including a separate safety microprocessor, which separately monitors cuff pressure and can shutdown the pump and open the valves in the event of a fault.

The NIBP information is displayed on the screen and printed on the chart. The MHR information is only valid at the time of the measurement and is displayed for a limited time - but only if no continuous method of obtaining MHR (ECG or SpO2) is available.

Interface with the patient is via an air tube only, which provides total electrical isolation.

5.4.2.7 Display

The FM800E uses a colour TFT Liquid Crystal Display with a resolution of 320x240 dots (1/4 VGA). This is used to display the following information:

Fetal heart rate (FHR) from ultrasound channels 1 and/or 2. .
Uterine contractions from the Toco/IUP channel. .
Fetal or Maternal heart rate (FHR or MHR) from fetal or maternal ECG. ●
Maternally sensed Fetal Events in the form of an on-screen message. .
MECG or FECG waveform trace or "baby" graphic. .
CTG Trace. The unit stores in excess of 24 hours of trace data and this can be recalled and � displayed on screen.
Maternal oxygen saturation and heart rate (FM830E only). .
Maternal blood pressure and heart rate (FM830E only). .

In general, information is colour matched to the connectors used for the different channels - e.g. green for ultrasound, pink for toco/IUP, white for ECG.

The display is also used for configuration with the front panel "soft" buttons. Parameters that can be changed include:

. Alert (alarm) thresholds.
Time and date. .
Patient details.
Printer settings (speed, headings)
International settings (language, date format etc.). .
"Baby" graphic and FECG/MECG waveform display.
"Easinote" defaults (pre-entered chart annotation text).
Interface settings.

{5}------------------------------------------------

5:4.2.8 Printer

The FM800E incorporates a chart recorder that provides a hard copy printout on continuous "fan fo thermal paper. Long life (25 year) archival paper is available.

Print speed can be set to 1, 2 or 3 cm/s.

The monitor incorporates a number of dedicated front panel buttons and indicators for printer control as follows:

. Printer on/off (with indicator)
Paper Advance t
"Easinotes" annotation

The chart content varies according to the model (FM820E or FM830E), and which transducers and sensors are connected, but can include:

Patient and hospital information (header)
Date and time
Fetal heart rate (FHR) from ultrasound channels 1 and/or 2. t
Uterine contractions from the Toco/IUP channel. 0
Fetal or Maternal heart rate (FHR or MHR) from fetal or maternal ECG. .
Maternally sensed Fetal Events in the form of printed markers.
"Easinote" annotation text.
Cross-channel heart rate coincidence warnings.
Maternal oxygen saturation and heart rate (FM830E only).
Maternal blood pressure and heart rate (FM830E only).

Impending paper exhaustion is signalled by a coloured band pre-printed on the paper. A sensor detects when the paper is exhausted, or the printer tray is removed; up to ten minutes of trace data are stored in memory, giving adequate time to change the paper pack. The buffered data are then printed, ensuring that there are no gaps in the printout.

5.4.2.9 Interfaces

The FM800E incorporates the following interfaces on the rear panel:

RS232 connection to Central Monitoring System.
RS232 connection to external device (future provision).
Ethernet connection to Central Monitoring System.

The RS232 and Ethernet links are electrically isolated from the main FM800E circuitry.

5.4.2.10 User Alerts

The monitor has the facility to provide audio/visual alerts to draw the operator's attention to any of the following occurrences:

Ultrasound: Signal loss. Heart rate goes above or below preset limits.
ECG: Disconnection. Signal loss. Heart rate goes above or below preset limits.
MSpO2: Signal loss. Maternal oxygen saturation falls below a preset limit. .
NIBP: Systolic or diastolic blood pressure go outside preset limits.
Maternal & Fetal heart rate coincidence.

All limits are determined by the user and are not themselves indicative of potential harm or the need for clinical intervention.

{6}------------------------------------------------

5.4.2.11 Audio Output

The FM800E incorporates a built-in loudspeaker. This is used for audible feedback of:

Ultrasound.
MECG/FECG. .
g Sp02.

Each has a characteristic sound, recognisable by clinicians, and helps in optimising the position of sensors and transducers in order to give the best signal.

The loudspeaker is also used to provide user feedback in the form of "beeps" to warn of alarm conditions etc.

There are three dedicated buttons on the front panel associated with the loudspeaker:

Channel select (US, ECG or Sp02). The selected channel is apparent from the display.
Volume Increase .
Volume Decrease

5.5 STATEMENT OF INTENDED USE

Huntleigh Healthcare Ltd Sonicaid FM800 Encore series fetal monitors are indicated for use in noninvasive and invasive monitoring of fetal and maternal vital signs during the intrapartum and antepartum periods.

Sonicaid FM820E provides comprehensive fetal monitoring facilities, offering twin ultrasound fetal heart rate, fetal or maternal ECG channel, external and internal uterine activity monitoring and maternally sensed fetal movements.

Sonicald FM830E additionally provides maternal monitoring with the facility for simultaneous monitoring of maternal pulse oximetry and non-invasive blood pressure.

The device is intended for use by healthcare professionals for monitoring fetal and adult patients in clinical and hospital-type facilities. It is not intensive care units, operating rooms or in transport monitoring applications.

The FM820/830 Encore is not intended for use with patients fitted with cardiac pacemakers, during defibrillation, while undergoing surgery, or while MRI scanning is taking place.

{7}------------------------------------------------

5.6 SUMMARY OF TECHNOLOGICAL CHARACTERISTICS COMPA PREDICATE DEVICES

Diagnostic Products Division

いらい

Note that further predicate device comparison information can be found in section 12 of this submission.

5.6.1 Comparison with Sonicaid FM830 (K002150)

This summary compares the Sonicaid FM830E to the legally marketed predicate device, the Sonicaid FM830 (K002150). The FM820E contains a subset of the FM830E (and is similar to the FM820).

CHARACTERISTIC	Predicate DeviceSonicaid FM830 (K002150)	Submitted DeviceSonicaid FM830 Encore	RATIONALE
Human Interface
Display	Monochrome Electro-luminescent 320x240	Colour LCD 320x240	Colour display => clearer userinterface. Reduced powerconsumption.
Controls	Membrane type pushbuttons with dedicated and"soft" keys.	Membrane type pushbuttons with dedicated and"soft" keys.	Same.
Printer	128mm Thick Film ThermalArray, 8 dots/mm.	128mm Thick Film ThermalArray, 8 dots/mm.	Same.
Connectors
Front	Ultrasound1&2	U'sound 1& 2: Nikolay12-pole, Yellow & Blue	U'sound 1& 2: Nikolay12-pole, Green x2	New ultrasound transducers notcompatible with FM800
	Toco/IUP	Nikolay 12-pole, Pink	Nikolay 12-pole, Pink	Same. Transducers are compatible
	FECG	Nikolay 12-pole, Blue (sharedwith US2).	Nikolay 12-pole, White(shared with MECG)	FECG no longer shared with US2.Electrode system is compatible.
	MECG	Nikolay 12-pole, Blue	Nikolay 12-pole, White(shared with FECG)	Connectors keyed differently.MECG electrode system iscompatible.
	MSpO2	Odu 12-Pole, Metal	Odu 12-Pole, Plastic	Plastic connector improves patientisolation.
	NIBP	Pneumatic	Pneumatic	Same.
Rear	RS232 (CRS)	9-Way "D-type" (F) x1	9-Way "D-type" (F) x1	Same.
	RS232(Unallocated)	9-Way "D-type" (F) x2	9-Way "D-type" (F) x1	Same type, quantity reduced dueto redundancy.
	RS485 (Axis)	6-Pole PCC x1		Axis system now obsolete.
	VGA(Ext. Monitor)	15-Way HD "D-type" (F) x1		External monitor not supported -clinically redundant.
Side	Ethernet		RJ45 x1	Improves CRS connection options.
	Event Marker	6.35mm Jack x2	6.35mm Jack x2	Same
Power Requirements
Voltage	Auto-switches in two ranges:100-120 & 200-240.	90-240Vac.	Increased supply flexibility.
Consumption	100VA max.	100VA max.	Same.
Ultrasound
	Transducers - Physical	74x27mm (Dia x Height)7-element piezo	79x27mm (Dia x Height)8-element piezo	Similar.
	Transducers -Frequency	1.5MHz (US1) and 2MHz(US2)	1MHz (both channels)	Improved pickup & discriminationin conjunction with new software.Product rationalisation.

CHARACTERISTIC	Predicate DeviceSonicaid FM830 (K002150)	Submitted DeviceSonicaid FM830 Encore	RATIONALE
Signal Processing	Analogue/Digital	Analogue/Digital	Similar (new DSP algorithmsintroduced for improved detectionover a wider range of conditions).
Measured AcousticOutput (Ispta)FDA Track 1	1.5MHz: 11mW cm-22.0MHz: 7.3mW cm-2	2.1mW cm-2	Superior signal processing hasenabled a reduction in acousticpower output.
Audio Feedback	Analogue	Digital	At 1MHz, raw analogue Dopplerfrequency is too low for goodaudibility. Improved artefactrejection.
Safety	Insulated transducer	Insulated transducer	Same
Tocograph
Transducers - Physical	Floating piston type withadhesive membrane.	New moulding, similar to u/swith overmoulded elastomerfaceplate.	Lower maintenance. Improvedpatient comfort. Easier to clean,reduced chance of infection.
Transducers -Functional	Double strain gauge/springassembly.	Double strain gauge/springassembly.	Same.
Signal Processing	Analogue/digital.	Analogue/digital. improvedprocessing algorithms.	Product improvement
Safety	Insulated transducer +isolation Barrier.	Insulated transducer +isolation Barrier.	Same.
IUP
Compatible Probes	Intran Plus IUP 400(K955443)	Intran Plus IUP 400(K955443)	Same.
Safety	Insulated transducer +isolation Barrier.	Insulated transducer +isolation Barrier.	Same.
MECG/FECG
Compatible Electrodes- MECG	Not known	Skintact F-TB (K040249)	Comparison not possible.
Compatible Electrodes- FECG	Graphic Controls (K905830)	Safelinc Fetal Spiral Electrode(K904745)GE Quik-Connect SpiralElectrode (K911657)	Options are legally marketed andare validated for use with thesubmitted device.
Signal Processing	Analogue/digital.	Analogue/digital (enhanced)	Performance improvement undersub-optimal conditions.
Safety	CF level protection.	CF level protection.	Same (BF is minimumrequirement).
NIBP
OEM Technology	Suntech Alta	Suntech Advantage	Alta modules no longer produced.Superseded by Advantage.
Compatible Cuffs	Not known	Suntech APC series(K051904)	Comparison not possible.
Maternal Temp.
Function	Included on FM830	Not included	Not clinically beneficial.
Accessories
Wall Bracket	Not known	Huntleigh HealthcareACC223	Comparison not possible.
Trolley	Not known	Huntleigh Healthcare	Comparison not possible.
CHARACTERISTIC	Predicate DeviceSonicaid FM830 (K002150)	Submitted DeviceSonicaid FM830 Encore	RATIONALE
Software
CTG Trace	Not implemented	Trace data stored in memoryfor review on screen - up to72 hours.	Product improvement.

Huntleigh Healthcare Ltd.

Page 5.8 FM800E FDA 510(k) Premarket Notification

{8}------------------------------------------------

Diagnostic Products Division Iन UNILLIG

ット..

、「

{9}------------------------------------------------

5.6.1 Comparison with RDT Tempus IC™ Patient Monitor (K082718)

The OEM technology for the Maternal SpO2 function differs in the Sonicaid FM830E from the Sonicaid FM830 (K002150). In respect of this function, the submitter claims Substantial Equivalence to another predicate device – the Tempus IC™ Patient Monitor (K082718) manufactured by Remote Diagnostic Technologies Limited of The Old Coach House, The Avenue, Farleigh Wallop, Hampshire, RG25 2HT, United Kingdom.

CHARACTERISTIC	Predicate DeviceTempus ICTM (K082718)	Submitted DeviceSonicaid FM830 Encore	RATIONALE
MSPO2
OEM Technology	BCI (Smiths Medical)WW3711 "B2"	BCI (Smiths Medical)WW3711 "B2"	Same.
Compatible Sensors	Proprietary.	BCI Adult Comfort Clip 3444(K974697)Nellcor Durasensor DS-100A(K863784)	Use of BCI 3444 and NellcorDS-100A is supported by BCIclinical trials (see section 12 forfurther details).

{10}------------------------------------------------

5.7 TESTS CARRIED OUT IN SUPPORT OF A DETERMINATION OF SU EQUIVALENCE

Diagnostic Products Division

5.7.1 Non-Clinical Tests

Electrical safety is to be confirmed by testing to the requirements of IEC 60601-1: 1988 and EN 60601-1-1: 2000.

Electromagnetic compatibility (EMC) is to be confirmed by testing to the requirements of IEC 60601-1-2: 2007.

Substantial equivalence to the FM800 predicate device (K002150) is confirmed by comparative bench testing. See document 7515101 - FM800E Comparative Bench Test Summary, which can be found in section 18 of this submission.

No specific tests have been carried out by Huntleigh Healthcare to support substantial equivalence to the Tempus IC 100 Patient Monitor (K082718). However, this uses the same OEM module (BCI WW3711) as used in the FM830E, and the aim of the bench tests carried out in this regard has been to verify that the raw data output from the OEM module is correctly displayed and printed on the FM830. See document 7514502 – FM800E MsP02 Verification Protocol & Results, which can be found in section 18 of this submission.

5.7.2 Clinical Tests

No specific clinical tests were carried out to determine substantial equivalence. However, this submission references clinical trials carried out by the OEM providers of the SpO2 technology to validate the use of the specified finger sensors.

User evaluation trials are to be carried out to verify the effectiveness of the FM830E in clinical situations. This submission includes a copy of the proposed User Evaluation Trial protocol.

See section 20 of this submission for further details.

5.8 CONCLUSIONS

5.8.1 Safety

The Electrical Safety and EMC tests to be carried out on the Sonicaid FM830E will confirm that it is at least as safe as the Sonicaid FM830 (K002150) predicate device.

5.8.2 Effectiveness

The FM830E has been designed to provide improved performance, clearer presentation of information and easier use compared with the FM830 predicate device (K002150). This is to be confirmed by User Evaluation trials in clinical situations in the home market.

5.8.3 Performance

Comparative bench tests confirm that the performance of the Sonicaid FM830E is at least as good as the Sonicaid FM830 (K002150) predicate device.

The overall conclusion is that the FM820/830E is as safe, as effective, and performs as well as, or better than, the FM820/830 (K002150) predicate device.

{11}------------------------------------------------

Image /page/11/Picture/0 description: The image shows the logo for the U.S. Department of Health and Human Services. The logo consists of a circular seal with the words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the perimeter. Inside the circle is a stylized graphic of three abstract shapes that resemble a human figure.

DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

JUL 15 2009

Mr. Graham Booth Technical Manager - Obstetric Products Huntleigh Healthcare Limited Diagnostic Products Division 35 Portmanmoor Road Cardiff, CF24 5HN UNITED KINGDOM

K090285 Re:

Trade/Device Name: Sonicaid FM820 & FM830 Encore Series Fetal Monitors Regulation Number: 21 CFR §884.2740 Regulation Name: Perinatal monitoring system and accessories Regulatory Class: II Product Code: HGM Dated: June 9, 2009 Received: June 11, 2009

Dear Mr. Booth:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical

{12}------------------------------------------------

device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled. "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/cdrh/mdr/ for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Mannfacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

Jadine M. Morris

Janine M. Morris Acting Director, Division of Reproductive, Abdominal, and Radiological Devices Office of Device Eyaluation Center for Devices and Radiological Health

Enclosure

{13}------------------------------------------------

Huntleigh Healthcare Limited | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

Indications For Use

510(k) Number:

K090285

Device Name:

Sonicaid FM820/830 Encore

Indications for Use:

Sonicaid FM820E is suitable for use when there is a need to monitor the following physiological parameters:

. Single or twin fetal heart rates by means of ultrasound
◆ Fetal or maternal heart rate via ECG
Uterine activity externally or internally sensed .
. Fetal movement - maternally sensed.

Sonicaid FM830E is suitable for use when there is a need to monitor the following physiological parameters:

. Single or twin fetal heart rates by means of ultrasound
. Fetal or maternal heart rate via ECG
Uterine activity externally or internally sensed .
Fetal movement - maternally sensed.
. Maternal heart rate and oxygen saturation via pulse oximetry
. Maternal non-invasive blood pressure

Image /page/13/Figure/20 description: The image shows two options for drug use: prescription use and over-the-counter use. The prescription use option is marked with "YES" and includes the text "(Part 21 CFR 801 Subpart D)". The over-the-counter use option is marked with "NO" and includes the text "(Part 21 CFR 801 Subpart C)". The text "AND/OR" is placed between the two options.

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Page 1 of 1

Hulu Rumm

(Division Sign-Off)
Division of Reproductive, Abdominal,
and Radiological Devices K090285
510(k) Number

Regulation Number and Section

§ 884.2740 Perinatal monitoring system and accessories.

(a)
Identification. A perinatal monitoring system is a device used to show graphically the relationship between maternal labor and the fetal heart rate by means of combining and coordinating uterine contraction and fetal heart monitors with appropriate displays of the well-being of the fetus during pregnancy, labor, and delivery. This generic type of device may include any of the devices subject to §§ 884.2600, 884.2640, 884.2660, 884.2675, 884.2700, and 884.2720. This generic type of device may include the following accessories: Central monitoring system and remote repeaters, signal analysis and display equipment, patient and equipment supports, and component parts.(b)
Classification. Class II (performance standards).